Intergrin has raised financing provided by Kartesia
Intergrin has obtained a unitranche loan of approximately US$59 million to refinance existing debt and to further support the growth of different healthcare and well-being initiatives.
Intergrin is a Dutch healthcare provider that operates clinics focused on specialized mental healthcare through its two brands, Het Rughuis and PHI. The company is headquartered in Geleen and currently has twelve treatment locations across the south of the country. Het Rughuis provides psychosomatic treatments to individuals with spine-related pain disorders through a combination of expert cognitive behavioral therapy, lifestyle-as-a-medicine therapy, vitality and physical therapy. PHI offers specialized psychosomatic mental healthcare to those suffering from anxiety, depression, somatoform disorder and serious unexplained physical complaints. Intergrin has unrivalled high success rates and delivers sustainable results, thereby significantly improving the quality of life of patients while also lowering the medical costs to society.
The loan was provided by Kartesia, a pan-European, independent and privately owned specialist provider of financing solutions, focused on offering customized resources across the capital structure to leading mid-market companies from a wide range of industries, with the view to accelerate their pace of growth.
Oaklins’ debt advisory team in the Netherlands advised Intergrin in this transaction and assisted in establishing a financing package aligned with the current business profile and future growth ambitions. This transaction emphasizes Oaklins’ strong track record in the healthcare clinics sector, which previously included deals such as Tandarts Today, Curious Kids and Dutch Dental Group.
Ron Joosten and Marc Kuijpers
Founders, Intergrin
Talk to the deal team
Niels Vermuë
Oaklins Netherlands
Related deals
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Learn moreCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Learn morePanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production
PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.
Learn more